On behalf of the CF community, the Cystic Fibrosis Foundation has expressed its concern to the Social Security Administration (SSA) about a proposed rule that could make it more difficult for people with CF to receive disability benefits.
The U.S. Food and Drug Administration (FDA) has approved TOBI® Podhaler™ (tobramycin inhalation powder), a dry powder formulation of the antibiotic TOBI, to treat lung infections caused by the bacteria Pseudomonas aeruginosa (P. aeruginosa).
The Cystic Fibrosis Foundation recently updated its Infection Prevention and Control Policy for all Foundation events, meetings and offices to protect the health of people with cystic fibrosis.
It was the year of 1957 when Phyllis Kossoff, one of the earliest volunteers of the Cystic Fibrosis Foundation and mother of a child with CF, found herself standing before a room of women, asking for help.
Tommy Danger didn't know it then, but the day his best friend's son was born was the day Tommy's life changed forever.